A Phase 3 interventional study of Saizen® and Saizen® in Small Gestational Age (SGA), sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-09-26.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multicentric, open-label, randomized, pilot comparative study in parallel groups comparing 1 group of subjects receiving 0.057 milligram/kilogram/day (mg/kg/day) or 0.40 mg/kg/week of Saizen® during 1 year to 1 group receiving 0.035 mg/kg/day (0.24 mg/kg/week) of Saizen® during 1 year after an initial 3-year treatment of recombinant human growth hormone (r-hGH) therapy with 0.057 mg/kg/day in both groups.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for inclusion / randomization into this study, the subjects must fulfill all of the following criteria (if there is no inclusion phase, the inclusion criteria will be considered as inclusion criteria for randomization):
Exclusion Criteria:
To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than \[\<\] -2 SDS or greater than \[\>\] -2 SDS)
Drug: Saizen®
Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (\< -2 SDS or \> -2 SDS)
Drug: Saizen®
Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Also known as: somatropin
Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Also known as: somatropin
Height Velocity
Height Velocity (HV) is the change in height since the previous year´s measurement and more precisely: HV = {(h-hp)/(d-dp)} \* 365.25 \[centimeter (cm)/year\] where h is current height in cm, hp is previous height in cm, closest to 1 year previous, d is the current date and dp is the date of measurement of previous height, closest to 1 year previous. Additionally, d and dp have to be within 0.6 years and 1.5 years. HV is the mean height velocity over the interval between d and dp but is displayed as HV at d.
Time frame: Month 12
Change From Baseline in Height-Standard Deviation Score (H-SDS) at Month 6 and Month 12
Height-Standard Deviation Score (H-SDS) was calculated as height minus mean (age-and sex-matched reference) divided by standard deviation (SD) \[age and sex-matched reference\]. Greater H-SDS indicates greater height.
Time frame: Baseline (randomization), Month 6 and Month 12
Height Velocity-Standard Deviation Score (HV-SDS)
Height Velocity-Standard Deviation Score (HV-SDS) was calculated as height velocity minus reference mean height velocity divided by SD of the reference mean height velocity. Greater HV-SDS indicates greater height velocity.
Time frame: Month 6 and Month 12
Change From Baseline in Height at Month 6
Time frame: Baseline (randomization) and Month 6
Change From Baseline in Bone Age at Month 12
Bone age was assessed by a left wrist X-Ray and evaluated by the investigator according to the Greulich and Pyle method.
Time frame: Baseline (randomization) and Month 12
Insulin Like Growth Factor-1 (IGF-1) Levels
Time frame: Baseline (randomization), Month 6 and Month 12
Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels
Time frame: Baseline (randomization), Month 6 and Month 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse Events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the Investigational Medicinal Product (IMP).
Time frame: Baseline (randomization) until Month 12
| Milestone | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Started | 10 | 12 |
| Completed | 10 | 11 |
| Not completed | 0 | 1 |
| Withdrew: Technical problem | 0 | 1 |
Height Velocity (HV) is the change in height since the previous year´s measurement and more precisely: HV = {(h-hp)/(d-dp)} \* 365.25 \[centimeter (cm)/year\] where h is current height in cm, hp is previous height in cm, closest to 1 year previous, d is the current date and dp is the date of measurement of previous height, closest to 1 year previous. Additionally, d and dp have to be within 0.6 years and 1.5 years. HV is the mean height velocity over the interval between d and dp but is displayed as HV at d.
| centimeter (cm)/year | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Height Velocity | 6.40 ± 1.35 | 4.40 ± 1.15 |
Height-Standard Deviation Score (H-SDS) was calculated as height minus mean (age-and sex-matched reference) divided by standard deviation (SD) \[age and sex-matched reference\]. Greater H-SDS indicates greater height.
| standard deviation score | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Baseline (randomization) | -1.30 ± 0.42 | -1.50 ± 0.37 |
| Change at Month 6 | 0.30 ± 0.22 | 0.10 ± 0.10 |
| Change at Month 12 | 0.30 ± 0.30 | -0.10 ± 0.24 |
Height Velocity-Standard Deviation Score (HV-SDS) was calculated as height velocity minus reference mean height velocity divided by SD of the reference mean height velocity. Greater HV-SDS indicates greater height velocity.
| standard deviation score | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Month 6 (n= 10,11) | 0.60 ± 0.44 | 0.10 ± 0.22 |
| Month 12 (n=10,12) | 0.30 ± 0.29 | -0.10 ± 0.24 |
| cm | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Baseline (randomization) | 121.10 ± 7.99 | 119.20 ± 5.29 |
| Change at Month 6 | 3.60 ± 1.31 | 2.50 ± 0.99 |
Bone age was assessed by a left wrist X-Ray and evaluated by the investigator according to the Greulich and Pyle method.
| years | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Baseline (randomization) (n = 9,10) | 7.50 ± 0.82 | 7.00 ± 1.85 |
| Change at Month 12 (n=9,7) | 1.40 ± 0.79 | 1.40 ± 0.89 |
| microgram/liter (mcg/L) | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Baseline (randomization) (n= 10,11) | 319.60 ± 146.27 | 275.40 ± 98.82 |
| Month 6 (n= 9,7) | 369.30 ± 120.13 | 262.40 ± 65.52 |
| Month 12 (n=10,10) | 414.30 ± 176.70 | 263.00 ± 120.70 |
| milligram/L (mg/L) | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Baseline (randomization) (n= 10,10) | 3.40 ± 0.70 | 3.40 ± 0.60 |
| Month 6 (n= 9,7) | 3.00 ± 0.84 | 3.30 ± 0.81 |
| Month 12 (n= 9,10) | 3.60 ± 1.02 | 3.50 ± 0.77 |
Adverse Events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the Investigational Medicinal Product (IMP).
| participants | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 2 | 1 |
Collected over Adverse Events (AEs) are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until 4 weeks post drug administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saizen® 0.057 mg/kg/Day | — | 0/10 (0%) | 2/10 (20%) |
| Saizen® 0.035 mg/kg/Day | — | 0/12 (0%) | 1/12 (8.3%) |
| Event | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day |
|---|---|---|
| BronchitisInfections and infestations | 1/10 | 0/12 |
| Ear infectionInfections and infestations | 1/10 | 0/12 |
| Insulin-like growth factor increasedInvestigations | 1/10 | 0/12 |
| AsthmaImmune system disorders | 0/10 | 1/12 |
| Age, Continuous(years) | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 8.00 ± 1.49 | 7.90 ± 0.90 | 8.00 ± 1.17 |
| Sex: Female, Male(Participants) | Saizen® 0.057 mg/kg/Day | Saizen® 0.035 mg/kg/Day | Total |
|---|---|---|---|
| Female | 4 | 4 | 8 |
| Male | 6 | 8 | 14 |
No study locations are listed for this record.
Ran from Feb 2005 to primary completion in Sep 2007, 31 months.
Results were first posted in Oct 2012, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →